Yeah, R&D costs nearly doubled this quarter compared to the last 4C.
James has cut this extremely close to the bone. Really, borderline a going concern. I significantly sold down my holding to match the increased risk, but I will retain the rest because there is obviously an enormous need if only their translational research manages to carry them through to the other side of the valley of death.
Clearly, even factoring in grants and upcoming rebates, another capital raise is sorely needed.
RCE Price at posting:
47.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)